Recent randomized trials have suggested that treatment with low molecular weight heparin
(LMWH) improves survival of cancer patients with venous thromboembolism, as compared …

The influence of unfractionated heparin (UFH) and other anticoagulants on the spread of
cancer has been reported since the early 1960s. 1 However, clinical studies investigating …

Monotherapy with low molecular weight heparin (LMWH) is superior to vitamin K antagonists
in preventing recurrent venous thromboembolism (VTE) in patients with cancer and may …

Patients with cancer are frequently treated with anticoagulants, including heparins, to treat or
to prevent thrombosis. Recent randomized trials that compared low molecular weight …

The association between cancer and thromboembolic disease is a well-known phenomenon
and can contribute significantly to the morbidity and mortality of cancer patients. The …

Two chemically modified heparins with low anticoagulant activity were studied in terms of
their antimetastatic activity in the B16-BL6 melanoma model. The two heparins were a very …

Cancer patients treated for venous thromboembolism with low molecular weight heparin
(LMWH) have a better survival rate than patients treated with unfractionated heparin (UFH) …

Essentials• Inhibition of tumor cell trans‐endothelial migration inhibits metastasis formation.•
Low molecular weight heparin (LMWH)‐mediated endothelial barrier protection was …

Heparin is frequently used in the treatment of cancer-associated thromboembolism.
Accumulating clinical evidence indicates that cancer patients treated with unfractionated and …

The metastatic spread of solid tumors is responsible for most cancer-related deaths, and
unfortunately no specific anti-metastatic therapy exists. Heparin is widely used in the clinic …